Skip to Main Content

Author Details

Rosalind A Eeles
The Institute of Cancer Research
1982
516
106
PMIDPaper TitleJournal TitlePublished Year
35995710Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer.Eur Urol Oncol2023
37932350Impact of germline DNA repair gene variants on prognosis and treatment of men with advanced prostate cancer.Sci Rep2023
37292833Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry.medRxiv2023
37025481Serum testosterone and prostate cancer in men with germline <i>BRCA1/2</i> pathogenic variants.BJUI Compass2023
37311464Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry.Am J Hum Genet2023
36872133Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry.Eur Urol2023
36609003Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention.Eur Urol2023
36494221Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.Eur Urol2023
36307647Age distribution and a multi-stage theory of carcinogenesis: 70 years on.Br J Cancer2023
34320204Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.J Natl Cancer Inst2022
35440417Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].Eur Urol2022
35436967How can we recruit more men of African or African-Caribbean ancestry into our research? Co-creating a video to raise awareness of prostate cancer risk and the PROFILE study.Res Involv Engagem2022
35659150Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.Eur Urol2022
35450835Microbiomes of Urine and the Prostate Are Linked to Human Prostate Cancer Risk Groups.Eur Urol Oncol2022
35450732Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.Eur Urol2022
35656509Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice.Front Oncol2022
33486571Genetic predisposition to prostate cancer: an update.Fam Cancer2022
35190596Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria.Sci Rep2022
35152271Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score.Prostate Cancer Prostatic Dis2022
35031163A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry.Eur Urol2022
34903604Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.Cancer Res2022
34923574Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.Br J Cancer2022
34127801Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24.Prostate Cancer Prostatic Dis2022
34214236The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening.BJU Int2022
32930425African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer.Int J Cancer2021
33904776Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening.Radiology2021
33623038Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.Nat Commun2021
33673083Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease.Cancers (Basel)2021
33630412Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer.J Pathol Clin Res2021
34790437Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk.Curr Genet Med Rep2021
34844712Genetics of prostate cancer and its utility in treatment and screening.Adv Genet2021
34678156A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.Lancet Oncol2021
33941403Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk.Eur Urol2021
33956343A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.Prostate2021
34355204Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals.HGG Adv2021
33249427FRMD6 has tumor suppressor functions in prostate cancer.Oncogene2021
32853339Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer.J Natl Cancer Inst2021
32532514Prostate Cancer Risk by BRCA2 Genomic Regions.Eur Urol2020
35050761Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.JCO Precis Oncol2020
31776447Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT.Prostate Cancer Prostatic Dis2020
32017261The New Genomics Era: Integration of genomics into mainstream oncology and implications for psycho-oncological care.Psychooncology2020
27141017Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Ann Oncol2019
29802810Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.BJU Int2019
31213659Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.Br J Cancer2019
31548585Publisher Correction: Shared heritability and functional enrichment across six solid cancers.Nat Commun2019
31537406Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.Eur Urol2019
31563410Patterns of recurrence after prostate bed radiotherapy.Radiother Oncol2019
31101764Identification of Novel Susceptibility Loci and Genes for Prostate Cancer Risk: A Transcriptome-Wide Association Study in Over 140,000 European Descendants.Cancer Res2019
30777372Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel.Eur Urol2019
30837682Correction: Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease.Br J Cancer2019
  • 1 - 50 of 516

Recommended Authors

Netherlands Cancer Institute
Career Start Year 2012
Number of shared co-authors 25
Mayo Clinic
Career Start Year 2007
Number of shared co-authors 50
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 76
National Cancer Institute, Frederick National Laboratory for Cancer Research
Career Start Year 2005
Number of shared co-authors 56
University of British Columbia
Career Start Year 2005
Number of shared co-authors 48
Guardant Health Inc.
Career Start Year 2004
Number of shared co-authors 20
Mayo Clinic
Career Start Year 2004
Number of shared co-authors 99
Clinical Investigations Branch, National Cancer Institute
Career Start Year 2004
Number of shared co-authors 21
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 44
Olivia Newton-John Cancer Research Institute
Career Start Year 2002
Number of shared co-authors 5
Institute for Computational Biomedicine
Career Start Year 2000
Number of shared co-authors 67
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 44
Institute for Human Genetics, University of California san francisco
Career Start Year 1998
Number of shared co-authors 53
Peter MacCallum Cancer Centre
Career Start Year 1998
Number of shared co-authors 67
Dana Farber Cancer Institute.
Career Start Year 1997
Number of shared co-authors 47
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 39
National Center for Advancing Translational Sciences
Career Start Year 1993
Number of shared co-authors 10
University of California los angeles
Career Start Year 1991
Number of shared co-authors 74
Stanford University
Career Start Year 1989
Number of shared co-authors 26
University of Sydney
Career Start Year 1989
Number of shared co-authors 37
Spanish National Cancer Research Centre
Career Start Year 1989
Number of shared co-authors 92
National Human Genome Research Institute, National Institutes of Health
Career Start Year 1988
Number of shared co-authors 55
Mt Sinai Hospital
Career Start Year 1988
Number of shared co-authors 38
Vanderbilt Genetics Institute, Vanderbilt University Medical Center
Career Start Year 1986
Number of shared co-authors 20
Johns Hopkins University School of Medicine
Career Start Year 1984
Number of shared co-authors 44
Karolinska Institute
Career Start Year 1984
Number of shared co-authors 54
Peter MacCallum Cancer Centre
Career Start Year 1982
Number of shared co-authors 98
University of Oxford
Career Start Year 1978
Number of shared co-authors 31
University of Washington
Career Start Year 1975
Number of shared co-authors 36
University of Trento
Career Start Year 1969
Number of shared co-authors 70

Collaborators

University of Cambridge
Co-authored papers 219
The Institute of Cancer Research
Co-authored papers 174
University of Oxford, John Radcliffe Hospital
Co-authored papers 76
Co-authored papers 73
University of Southern California
Co-authored papers 64
Fred Hutchinson Cancer Research Center
Co-authored papers 62
Karolinska Institute
Co-authored papers 58
University of Oxford
Co-authored papers 58
QIMR Berghofer Medical Research Institute
Co-authored papers 57
Co-authored papers 57
Co-authored papers 53
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 53
Institute of Biomedicine, University of Turku
Co-authored papers 52
Co-authored papers 52
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 51
Mayo Clinic
Co-authored papers 51
The Institute of Cancer Research
Co-authored papers 51
The Institute of Cancer Research
Co-authored papers 49
Mayo Clinic
Co-authored papers 49
Guy's and St Thomas' NHS Foundation Trust
Co-authored papers 48
QIMR Berghofer Medical Research Institute
Co-authored papers 48
Center for Cancer Equity and Engagement, Dana-Farber/Harvard Cancer Center
Co-authored papers 48
Perelman School of Medicine, University of Pennsylvania, USA Abramson Cancer Center
Co-authored papers 45
University of Utah
Co-authored papers 45
Pomeranian Medical University
Co-authored papers 43
Instituto de Salud Carlos III
Co-authored papers 42
Oncogenetics Team The Institute of Cancer Research London UK.
Co-authored papers 42
University of Toronto
Co-authored papers 41
Norwich Medical School, University of East Anglia
Co-authored papers 40
Co-authored papers 39